Business
Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center
Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\") today announced initial sales of SofPulse® units into a VA hospital in Texas. SofPulse® is Endonovo’s FDA-Cleared non-invasive device for reduction of postoperative pain and edema. SofPulse® represents a low-cost, drug-free solution to reduce use of opioids following surgical procedures and help prevent addiction. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse™ has been used effectively and studied extensively in soft tissue post-operative pain management. Learn more at www.sofpulse.com The Department of Veterans Affairs is a recognized leader utilizing proven strategies in pain management and opioid safety, and its success in reducing the use of opioids has been recognized by other health systems. The Veterans Affairs Texas hospital is one of the department's largest hospitals, serving 27 Counties in Texas, and offers state of the art treatment for complex surgical conditions while at the same time promoting a multimodal approach for the treatment of postoperative pain aimed at reducing narcotics, which now includes SofPulse®. Endonovo CEO Alan Collier stated, “I am extremely proud of our team and the effort to reach such a major milestone. Serving the veterans is an honor and privilege. Although the process was long and to become an approved vendor was a major accomplishment, we believe serving this VA Medical Center will open the doors for us to serve many other VA centers and assist with the VHA commitment in reducing opioid use.” About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radio...